Sirt1 regulates apoptosis and extracellular matrix degradation in resveratrol‑treated osteoarthritis chondrocytes via the Wnt/β‑catenin signaling pathways

Liu,Shuan; Yang,Hongping; Hu,Bing; Zhang,Mingyong

doi:10.3892/etm.2017.5165

Sirt1 regulates apoptosis and extracellular matrix degradation in resveratrol‑treated osteoarthritis chondrocytes via the Wnt/β‑catenin signaling pathways

Authors:
- Shuan Liu
- Hongping Yang
- Bing Hu
- Mingyong Zhang
View Affiliations

Affiliations: Department of Orthopaedics, Tianyou Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei 430064, P.R. China
Published online on: September 21, 2017 https://doi.org/10.3892/etm.2017.5165
Pages: 5057-5062

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteoarthritis (OA) has become a major public health problem with the increased aging population. Previous studies have demonstrated that resveratrol (RES) was able to increase the level of sirtuin 1 (Sirt1) in OA chondrocytes. However, further investigations are required to elucidate the precise molecular mechanism of RES and the potential link between Sirt1 and RES. Therefore, the present study used 30 clinical OA chondrocyte to examine chondrocyte viability, apoptosis rate and the mRNA and protein expression levels of Sirt1 and relevant genes implicated in apoptosis, extracellular matrix (ECM) degradation and Wnt/β‑catenin signaling pathway. RES and nicotinamide were used as the stimulus and inhibitor, respectively. The results demonstrated that the apoptotic rate reduced as the cell population decreased from 13.83 to 6.55% in response to 10 µM RES. Expression levels of B‑cell lymphoma 2 (Bcl‑2) associated X protein (Bax), procaspase‑3 and ‑9, matrix metalloproteinase 1 (MMP1), MMP3, MMP13, Wnt3a, Wnt5a, Wnt7a and β‑catenin were significantly inhibited (P<0.01), whereas the level of Bcl‑2 was significantly increased (P<0.01) in OA chondrocytes treated with 10 µM RES. These observations suggested that Sirt1 may regulate apoptosis and ECM degradation in RES‑treated osteoarthritis chondrocytes via the Wnt/β‑catenin signaling pathway.

View Figures

View References

1	Glyn-Jones S, Palmer AJ, Agricola R, Price AJ, Vincent TL, Weinans H and Carr AJ: Osteoarthritis. Lancet. 386:376–387. 2015. View Article : Google Scholar : PubMed/NCBI
2	Zhou X, Li W, Jiang L, Bao J, Tao L, Li J and Wu L: Tetrandrine inhibits the Wnt/β-catenin signalling pathway and alleviates osteoarthritis: An in vitro and in vivo study. Evid Based Complement Alternat Med. 2013:8095792013. View Article : Google Scholar : PubMed/NCBI
3	Gelber AC: In the clinic. Osteoarthritis. Ann Intern Med. 161:ITC1–ITC16. 2014. View Article : Google Scholar : PubMed/NCBI
4	Takamatsu A, Ohkawara B, Ito M, Masuda A, Sakai T, Ishiguro N and Ohno K: Verapamil protects against cartilage degradation in osteoarthritis by inhibiting Wnt/β-catenin signaling. PLoS One. 9:e926992014. View Article : Google Scholar : PubMed/NCBI
5	Blander G and Guarente L: The Sir2 family of protein deacetylases. Annu Rev Biochem. 73:417–435. 2004. View Article : Google Scholar : PubMed/NCBI
6	Seo JS, Moon MH, Jeong JK, Seol JW, Lee YJ, Park BH and Park SY: SIRT1, a histone deacetylase, regulates prion protein-induced neuronal cell death. Neurobiol Aging. 33:1110–1120. 2012. View Article : Google Scholar : PubMed/NCBI
7	Michan S and Sinclair D: Sirtuins in mammals: Insights into their biological function. Biochem J. 404:1–13. 2007. View Article : Google Scholar : PubMed/NCBI
8	Yamamoto H, Schoonjans K and Auwerx J: Sirtuin functions in health and disease. Mol Endocrinol. 21:1745–1755. 2007. View Article : Google Scholar : PubMed/NCBI
9	Dvir-Ginzberg M, Gagarina V, Lee EJ and Hall DJ: Regulation of cartilage-specific gene expression in human chondrocytes by SirT1 and nicotinamide phosphoribosyltransferase. J Biol Chem. 283:36300–36310. 2008. View Article : Google Scholar : PubMed/NCBI
10	Fujita N, Matsushita T, Ishida K, Kubo S, Matsumoto T, Takayama K, Kurosaka M and Kuroda R: Potential involvement of SIRT1 in the pathogenesis of osteoarthritis through the modulation of chondrocyte gene expressions. J Orthop Res. 29:511–515. 2011. View Article : Google Scholar : PubMed/NCBI
11	Abed É, Couchourel D, Delalandre A, Duval N, Pelletier JP, Martel-Pelletier J and Lajeunesse D: Low sirtuin 1 levels in human osteoarthritis subchondral osteoblasts lead to abnormal sclerostin expression which decreases Wnt/β-catenin activity. Bone. 59:28–36. 2014. View Article : Google Scholar : PubMed/NCBI
12	Matsushita T, Sasaki H, Takayama K, Ishida K, Matsumoto T, Kubo S, Matsuzaki T, Nishida K, Kurosaka M and Kuroda R: The overexpression of SIRT1 inhibited osteoarthritic gene expression changes induced by interleukin-1β in human chondrocytes. J Orthop Res. 31:531–537. 2013. View Article : Google Scholar : PubMed/NCBI
13	Yadav M, Jain S, Bhardwaj A, Nagpal R, Puniya M, Tomar R, Singh V, Parkash O, Prasad GB, Marotta F and Yadav H: Biological and medicinal properties of grapes and their bioactive constituents: An update. J Med Food. 12:473–484. 2009. View Article : Google Scholar : PubMed/NCBI
14	Lei M, Wang JG, Xiao DM, Fan M, Wang DP, Xiong JY, Chen Y, Ding Y and Liu SL: Resveratrol inhibits interleukin 1β-mediated inducible nitric oxide synthase expression in articular chondrocytes by activating SIRT1 and thereby suppressing nuclear factor-κB activity. Eur J Pharmacol. 674:73–79. 2012. View Article : Google Scholar : PubMed/NCBI
15	Wang J, Gao JS, Chen JW, Li F and Tian J: Effect of resveratrol on cartilage protection and apoptosis inhibition in experimental osteoarthritis of rabbit. Rheumatol Int. 32:1541–1548. 2012. View Article : Google Scholar : PubMed/NCBI
16	Kim H, Braun H and Dragoo J: The effect of resveratrol on normal and osteoarthritic chondrocyte metabolism. Bone Joint Res. 3:51–59. 2014. View Article : Google Scholar : PubMed/NCBI
17	Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke T, Greenwald R, Hochberg M, et al: Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 29:1039–1049. 1986. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Xie J, Zhang X and Zhang L: Negative regulation of inflammation by SIRT1. Pharmacol Res. 67:60–67. 2013. View Article : Google Scholar : PubMed/NCBI
20	Takayama K, Ishida K, Matsushita T, Fujita N, Hayashi S, Sasaki K, Tei K, Kubo S, Matsumoto T, Fujioka H, et al: SIRT1 regulation of apoptosis of human chondrocytes. Arthritis Rheum. 60:2731–2740. 2009. View Article : Google Scholar : PubMed/NCBI
21	Gabay O, Oppenhiemer H, Meir H, Zaal K, Sanchez C and Dvir-Ginzberg M: Increased apoptotic chondrocytes in articular cartilage from adult heterozygous SirT1 mice. Ann Rheum Dis. 71:613–636. 2012. View Article : Google Scholar : PubMed/NCBI
22	Kevorkian L, Young DA, Darrah C, Donell ST, Shepstone L, Porter S, Brockbank SM, Edwards DR, Parker AE and Clark IM: Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum. 50:131–141. 2004. View Article : Google Scholar : PubMed/NCBI
23	Murphy G, Knauper V, Atkinson S, Butler G, English W, Hutton M, Stracke J and Clark I: Matrix metalloproteinases in arthritic disease. Arthritis Res. 4 Suppl 3:S39–S49. 2002. View Article : Google Scholar : PubMed/NCBI
24	Tetlow LC, Adlam DJ and Woolley DE: Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: Associations with degenerative changes. Arthritis Rheum. 44:585–594. 2001. View Article : Google Scholar : PubMed/NCBI
25	Davidson RK, Waters JG, Kevorkian L, Darrah C, Cooper A, Donell ST and Clark IM: Expression profiling of metalloproteinases and their inhibitors in synovium and cartilage. Arthritis Res Ther. 8:R1242006. View Article : Google Scholar : PubMed/NCBI
26	Liu FC, Hung LF, Wu WL, Chang DM, Huang CY, Lai JH and Ho LJ: Chondroprotective effects and mechanisms of resveratrol in advanced glycation end products-stimulated chondrocytes. Arthritis Res Ther. 12:R1672010. View Article : Google Scholar : PubMed/NCBI
27	Lei M: Resveratrol protects bone marrow mesenchymal stem cell derived chondrocytes cultured on chitosan-gelatin scaffolds from the inhibitory effect of interleukin-1beta. Acta Pharmacol Sin. 29:1350–1356. 2008. View Article : Google Scholar : PubMed/NCBI
28	Sassi N, Laadhar L, Allouche M, Achek A, Kallel-Sellami M, Makni S and Sellami S: WNT signaling and chondrocytes: From cell fate determination to osteoarthritis physiopathology. J Recept Signal Transduct Res. 34:73–80. 2014. View Article : Google Scholar : PubMed/NCBI
29	Yuasa T, Otani T, Koike T, Iwamoto M and Enomoto-Iwamoto M: Wnt/β-catenin signaling stimulates matrix catabolic genes and activity in articular chondrocytes: Its possible role in joint degeneration. Lab Invest. 88:264–274. 2008. View Article : Google Scholar : PubMed/NCBI
30	Nalesso G, Sherwood J, Bertrand J, Pap T, Ramachandran M, De Bari C, Pitzalis C and Dell'accio F: WNT-3A modulates articular chondrocyte phenotype by activating both canonical and noncanonical pathways. J Cell Biol. 193:551–564. 2011. View Article : Google Scholar : PubMed/NCBI
31	Huh YH, Ryu JH and Chun JS: Regulation of type II collagen expression by histone deacetylase in articular chondrocytes. J Biol Chem. 282:17123–17131. 2007. View Article : Google Scholar : PubMed/NCBI
32	Sassi N, Laadhar L, Allouche M, Zandieh-Doulabi B, Hamdoun M, Klein-Nulend J, Makni S and Sellami S: The roles of canonical and non-canonical Wnt signaling in human de-differentiated articular chondrocytes. Biotech Histochem. 89:53–65. 2014. View Article : Google Scholar : PubMed/NCBI
33	Bernard NJ: Osteoarthritis: Repositioning verapamil-for Wnt of an OA treatment. Nat Rev Rheumatol. 10:2602014. View Article : Google Scholar : PubMed/NCBI